Trial Profile
An Open Label Study of the Effect of First Line Treatment With Avastin (Bevacizumab) in Combination With Low-Dose Interferon on Progression-Free Survival in Patients With Metastatic Clear Cell Renal Cell Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Dec 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Interferon alpha-2a (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms BEVLIN
- Sponsors Roche
- 18 Dec 2021 This trial has been completed in Italy, according to European Clinical Trials Database.(3 Feb 2012)
- 25 Jul 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 26 May 2015 Primary and secondary endpoints are amended.